See Shionogi-Sponsored Publications
Publications
Here, you can review available Shionogi-sponsored publications. If you would like an electronic copy of one of the journal publications on this page, please contact
Shionogi Medical Information for further assistance.
Information about investigational compounds or investigational uses of products does not imply FDA approval of these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the investigational compounds or investigational uses of products will receive FDA approval. Shionogi does not recommend or suggest use of its products in a manner inconsistent with FDA-approved labeling.
Antimicrobial snapshot: cefiderocol
Antimicrobial snapshot: cefiderocol
Effects of ensitrelvir on the pharmacokinetics of combined oral contraceptives (ethinyl estradiol/drospirenone) in healthy adult women: a phase 1 fixed-sequence, multiple-dose, drug–drug interaction study
Effects of ensitrelvir on the pharmacokinetics of combined oral contraceptives (ethinyl estradiol/drospirenone) in healthy adult women: a phase 1 fixed-sequence, multiple-dose, drug–drug interaction study
Understanding mechanisms of reduced cefiderocol susceptibility in pvdS and fecI mutants of Pseudomonas aeruginosa
Understanding mechanisms of reduced cefiderocol susceptibility in pvdS and fecI mutants of Pseudomonas aeruginosa
Activity of cefiderocol against Pseudomonas aeruginosa from the USA and Europe (2020-2023) with difficult-to-treat resistance phenotype, including those nonsusceptible to recently developed β-lactam/β-lactamase inhibitor combinations: results from the SENTRY antimicrobial surveillance program
Activity of cefiderocol against Pseudomonas aeruginosa from the USA and Europe (2020-2023) with difficult-to-treat resistance phenotype, including those nonsusceptible to recently developed β-lactam/β-lactamase inhibitor combinations: results from the SENTRY antimicrobial surveillance program
Cefiderocol treatment for patients infected by Stenotrophomonas maltophilia, Burkholderia cepacia complex and Achromobacter spp.: subgroup analysis from the PERSEUS study
Cefiderocol treatment for patients infected by Stenotrophomonas maltophilia, Burkholderia cepacia complex and Achromobacter spp.: subgroup analysis from the PERSEUS study